SynBiotic's Annual General Meeting Approves Growth Plans with Over 99% Approval

In a strong show of support, SYNBIOTIC SE's Annual General Meeting confirmed the company's strategic growth plans with over 99 percent approval. The meeting, held virtually on September 20, 2024, was chaired by Oliver Conrad, with notable attendance by CEO Daniel Kruse and entrepreneur Frank Otto. This overwhelming approval reflects confidence in SYNBIOTIC's direction for the current and upcoming year.

CEO Daniel Kruse highlighted disciplined cost optimization and strategic investments as key drivers for SYNBIOTIC's expected profitability by 2025. The company forecasts substantial sales growth, anticipating revenues of EUR 33.6 million by 2026, up from EUR 16.6 million in 2024. This financial trajectory is fueled by increased demand across all business areas.

SYNBIOTIC's share price, recently volatile due to broader economic impacts, including COVID-19 and the Ukraine conflict, is projected to reach EUR 12.50 by mid-2025. Legal reforms and robust strategic positioning have significantly boosted the medicinal cannabis market, further bolstering investor confidence.

Notably, the annual meeting also saw the election of new board members Malte Johannes and Daniel Kruse, alongside the company's relocation from Munich to Düsseldorf. The meeting underscored SYNBIOTIC's commitment to diversification within the industrial hemp and cannabis sector, a unique competitive advantage.